SCHEMBL651073

SCHEMBL651073

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(C(F)(F)F)cc1C(F)(F)F)CC1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 4/20 0.42
C5AR1 P21730 1/20 0.39
CRHR1 P34998 3/20 0.36
TRPV4 Q9HBA0 4/20 0.34
HDAC1 Q13547 1/20 0.34
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
ADORA1 P30542 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
TSHR P16473 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL646859 0.92 C5AR1 (0.39) CCR4C5AR1CRHR1TRPV4HDAC1
SCHEMBL649769 0.91 C5AR1 (0.40) CCR4C5AR1CRHR1TRPV4HDAC1
SCHEMBL5137300 0.91 CCR4 (0.49) CCR4C5AR1CRHR1HDAC1BCHE
SCHEMBL647762 0.91 C5AR1 (0.39) CCR4C5AR1CRHR1TRPV4HDAC1
SCHEMBL648934 0.88 CCR4 (0.40) CCR4C5AR1CRHR1HDAC1BCHE
SCHEMBL5134723 0.88 C5AR1 (0.42) CCR4C5AR1CRHR1BCHEPSEN1
SCHEMBL650435 0.87 C5AR1 (0.42) CCR4C5AR1CRHR1TRPV4ADORA1
SCHEMBL650021 0.87 C5AR1 (0.41) CCR4C5AR1CRHR1TRPV4HDAC1
SCHEMBL648150 0.87 C5AR1 (0.41) C5AR1CRHR1TRPV4HDAC1TSHR
SCHEMBL651739 0.86 CCR4 (0.45) CCR4C5AR1CRHR1HDAC1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed